Urticaria medical therapy: Difference between revisions
Jump to navigation
Jump to search
(→Others) |
|||
| Line 26: | Line 26: | ||
===Others=== | ===Others=== | ||
*[[Beta blockers]], such as [[propranolol]], have been effective in [[treatment]] of [[urticaria|adrenergic urticaria]].<ref name="pmid2865515">{{cite journal| author=Shelley WB, Shelley ED| title=Adrenergic urticaria: a new form of stress-induced hives. | journal=Lancet | year= 1985 | volume= 2 | issue= 8463 | pages= 1031-3 | pmid=2865515 | doi=10.1016/s0140-6736(85)90905-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2865515 }} </ref> | *[[Beta blockers]], such as [[propranolol]], have been effective in [[treatment]] of [[urticaria|adrenergic urticaria]].<ref name="pmid2865515">{{cite journal| author=Shelley WB, Shelley ED| title=Adrenergic urticaria: a new form of stress-induced hives. | journal=Lancet | year= 1985 | volume= 2 | issue= 8463 | pages= 1031-3 | pmid=2865515 | doi=10.1016/s0140-6736(85)90905-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2865515 }} </ref> | ||
*In simultaneous [[Mast cell tumor|mastocytosis]], [[PUVA]] showed to be effective due to it's effect on [[mast cell]] reduction.<ref name="pmid2425755">{{cite journal| author=Olafsson JH, Larkö O, Roupe G, Granerus G, Bengtsson U| title=Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study. | journal=Arch Dermatol Res | year= 1986 | volume= 278 | issue= 3 | pages= 228-31 | pmid=2425755 | doi=10.1007/BF00412929 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2425755 }} </ref><ref name="pmid10764986">{{cite journal| author=Horio T| title=Indications and action mechanisms of phototherapy. | journal=J Dermatol Sci | year= 2000 | volume= 23 Suppl 1 | issue= | pages= S17-21 | pmid=10764986 | doi=10.1016/s0923-1811(99)00069-9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10764986 }} </ref> | |||
*[[Tricyclic antidepressants]] such as [[doxepin]], also are often potent [[H1 antihistamine|H<sub>1</sub>]] and [[H2 antagonist|H<sub>2</sub> antagonists]] and may have a role in [[therapy]], although their [[Adverse effect (medicine)|side effects]] usually limit their use. | *[[Tricyclic antidepressants]] such as [[doxepin]], also are often potent [[H1 antihistamine|H<sub>1</sub>]] and [[H2 antagonist|H<sub>2</sub> antagonists]] and may have a role in [[therapy]], although their [[Adverse effect (medicine)|side effects]] usually limit their use. | ||
*As of 2008 an Australian company is performing [[clinical trials]] with an [[Analog (chemistry)|analogue]] of alpha-[[melanocyte-stimulating hormone]] called [[melanotan]] ( | *As of 2008 an Australian company is performing [[clinical trials]] with an [[Analog (chemistry)|analogue]] of alpha-[[melanocyte-stimulating hormone]] called [[melanotan]] ([[melanotan|CUV1647]]) for the [[treatment]] of [[urticaria|solar urticaria]], which is a type of [[urticaria]] that develops in response to exposure to specific wavelengths of light.<ref>{{cite web | url =http://www.emedicine.com/derm/topic448.htm | title = Urticaria, Solar | accessdate = 2007-12-26 | date =2007-03-29 | last = Baron |first = ED | coauthors = Taylor, CR | publisher = [[WebMD]] }}</ref><ref name="Australian_Life_Scientist">{{Cite web | url =http://www.biotechnews.com.au/index.php/id;444900667 | title = Tackling skin cancer in organ transplant patients | accessdate = 2007-12-24 | publisher=Australian Life Scientist | date = 2007-04-13 | last = McDonald | first = Kate }}</ref> | ||
===Contraindicated medications=== | ===Contraindicated medications=== | ||
Revision as of 17:50, 14 January 2021
|
Urticaria Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Urticaria medical therapy On the Web |
|
American Roentgen Ray Society Images of Urticaria medical therapy |
|
Risk calculators and risk factors for Urticaria medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Urticarias can be very difficult to treat. There are no guaranteed treatments or means of controlling attacks, and some sub-populations are treatment resistant, with medications spontaneously losing their effectiveness and requiring new medications to control attacks. It can be difficult to determine appropriate medications since some such as loratadine require a day or two to build up to effective levels, and since the condition is intermittent and outbreaks typically clear up without any treatment.
Most treatment plans for urticaria involve being aware of one's triggers, but this can be difficult since there are several different forms of urticaria and people often exhibit more than one type. Also, since symptoms are often idiopathic there might not be any clear trigger. If one's triggers can be identified then outbreaks can often be managed by limiting one's exposure to these situations.
Medical Therapy
Histamine Antagonists
- Antihistamines, such as diphenhydramine, hydroxyzine, cetirizine and other H1 receptor antagonists are recommended as the first line treatment for urticaria. These are taken on a regular basis for their protective effect, lessening or halting attacks.[1] These are taken on a regular basis for their protective effect, lessening or halting attacks.
- Furthermore H₂-receptor antagonists, such as cimetidine and ranitidine, may help to control symptoms either prophylactically or by relieving symptoms during an attack.[2]
- When H₂-receptor antagonists are taken in combination with H1 antihistamines, a synergistic effect is expected, which is more effective than either treatment alone.
- The use of ranitidine (or other H₂-receptor antagonists) for urticaria is considered an off-label use, since these drugs are primarily used for the treatment of peptic ulcer disease and gastroesophageal reflux disease.
- If the disease doesn't response to antihistamines, second line treatments are recommended.
Omalizumab
Cyclosporine
Cyclosporine A has been effective in some cases of urticaria by it's direct effect on liberation of the mast cell mediators, nevertheless due to it's high cost it is usually considered as an alternate treatment.[3][4]
Corticosteroids
- An oral corticosteroid, such as prednisone can sometimes be prescribed. In a randomized controlled trial done on adult who had urticaria with a duration less than 24 hours, a comparison between prednisone plus levocetirizine and levocetirizine alone, yielded 62% and 72% rates of resolution within two days, respectively.[5]
- Long term treatment must be avoided, due to high rates of adverse effects.[3]
Others
- Beta blockers, such as propranolol, have been effective in treatment of adrenergic urticaria.[6]
- In simultaneous mastocytosis, PUVA showed to be effective due to it's effect on mast cell reduction.[7][8]
- Tricyclic antidepressants such as doxepin, also are often potent H1 and H2 antagonists and may have a role in therapy, although their side effects usually limit their use.
- As of 2008 an Australian company is performing clinical trials with an analogue of alpha-melanocyte-stimulating hormone called melanotan (CUV1647) for the treatment of solar urticaria, which is a type of urticaria that develops in response to exposure to specific wavelengths of light.[9][10]
Contraindicated medications
Urticaria is considered an absolute contraindication to the use of the following medications:
References
- ↑ Greaves MW, Tan KT (2007). "Chronic Urticaria: Recent Advances". Clin Rev Allergy Immunol. 33 (1–2): 134–143. doi:10.1007/s12016-007-0038-3. PMID 18094952.
- ↑ Lee EE, Maibach HI (2001). "Treatment of urticaria. An evidence-based evaluation of antihistamines". Am J Clin Dermatol. 2 (1): 27–32. PMID 11702618.
- ↑ 3.0 3.1 Zuberbier T (2003). "Urticaria". Allergy. 58 (12): 1224–34. doi:10.1046/j.1398-9995.2003.00327.x. PMID 14616095.
- ↑ Stellato C, de Paulis A, Ciccarelli A, Cirillo R, Patella V, Casolaro V; et al. (1992). "Anti-inflammatory effect of cyclosporin A on human skin mast cells". J Invest Dermatol. 98 (5): 800–4. doi:10.1111/1523-1747.ep12499960. PMID 1373749.
- ↑ Barniol C, Dehours E, Mallet J, Houze-Cerfon CH, Lauque D, Charpentier S (2017). "Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial". Ann Emerg Med. doi:10.1016/j.annemergmed.2017.03.006. PMID 28476259.
- ↑ Shelley WB, Shelley ED (1985). "Adrenergic urticaria: a new form of stress-induced hives". Lancet. 2 (8463): 1031–3. doi:10.1016/s0140-6736(85)90905-5. PMID 2865515.
- ↑ Olafsson JH, Larkö O, Roupe G, Granerus G, Bengtsson U (1986). "Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study". Arch Dermatol Res. 278 (3): 228–31. doi:10.1007/BF00412929. PMID 2425755.
- ↑ Horio T (2000). "Indications and action mechanisms of phototherapy". J Dermatol Sci. 23 Suppl 1: S17–21. doi:10.1016/s0923-1811(99)00069-9. PMID 10764986.
- ↑ Baron, ED (2007-03-29). "Urticaria, Solar". WebMD. Retrieved 2007-12-26. Unknown parameter
|coauthors=ignored (help) - ↑ McDonald, Kate (2007-04-13). "Tackling skin cancer in organ transplant patients". Australian Life Scientist. Retrieved 2007-12-24.